Normed syrup 50mg ml 120ml
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Syrup Normed - refers to antiviral agents of direct action. Inosine pranobex consists of two components: inosine, the active component that is a purine metabolite, and salt of 4-acetamido benzoic acid with N, N-dimethylamino-2-propanol, an auxiliary component that increases the availability of inosine for lymphocytes. The active and auxiliary components are in the molar the ratio of 1: 3. The active substance inosine pranobex has a direct antiviral and immunomodulatory effects. Direct antiviral effect due to the binding of viral cells to the ribosomes, slows down the synthesis of viral messenger RNA (mRNK) and inhibits the replication of RNA and DNA-genomic viruses, mediated effect is due to the induction of interferon formation. In-vivo studies revealed that inosine pranobex activates lowered synthesis of messenger RNA (mRNK) of lymphocyte proteins and efficiency of the translation process with simultaneous inhibition of the synthesis of viral RNA in such mechanisms: the inclusion of inosine-related oro polyribosomes, inhibition of the addition of polyadenylic acid to viral messenger RNA (mRNK) and the restructuring of lymphocytic intramembranous plasma particles (IMP), which increases their density by almost three times. The immunomodulating effect is due to the effect on T-lymphocytes (activation of cytokine synthesis). phagocytic activity of macrophages. Inosine pranobex enhances the differentiation of pre-T-lymphocytes, stimulates mitogen-induced proliferation of T- and B-lymphocytes, increases the functional activity of T-lymphocytes, including their ability to form lymphokines, normalizes the ratio between the main regulatory subpopulations of CD4 + / CD8 + and contributes normalization of the formation of T-cell memory. Inosine pranobex significantly enhances the production of interleukin-2 (IL-2) by lymphocytes and promotes the expression of receptors for this interleukin on lymphoid cells, stimulated is the activity of natural killer cells (NK-cells), stimulates the activity of macrophages for phagocytosis, antigen processing and presentation, increases the antibody-producing cells in the body from the first days of treatment.Inosine pranobex also regulates the mechanisms of cytotoxicity of T lymphocytes and NK cells. Inosine pranobex stimulates the synthesis of interleukin-1 (IL-1), microbicide, expression of membrane receptors and the ability to respond to lymphokines and chemotactic factors. During well-known in vivo studies, there was a significant increase production of endogenous interferon gamma (IFN-γ) and a decrease in the production of interleukin-4 (IL-4). In case of a herpetic infection, the formation of specific antiherpetic antibodies is significantly accelerated, of sul and manifestations frequency retsidivov.Inozin pranobex postvirusnomu prevents weakening cellular RNA and protein synthesis in infected cells, which is especially important for the cells involved in the immune defense process of the organism. As a result of such a complex action, the viral load on the body is reduced, the activity of the immune system is normalized, the synthesis of its own interferons is significantly activated, which contributes to resistance to infectious diseases and the rapid localization of the source of infection if it occurs.
Active ingredients
Inosine pranobex
Release form
Syrup
Composition
Active ingredient: inosine pranobex, 100 ml of syrup contains 5 0 g of inosine pranobex, excipients: sucrose glycerin methyl paraben (E 218) propyl para-hydroxybenzoate (E 216) citrus fruit flavor, purified water.
Indications
Infectious diseases of viral etiology in patients with normal and low immune status: influenza parainfluenza acute respiratory viral infections bronchitis of viral etiology rhinovirus and adenoviral infections, epidemic parotitis measles. Diseases caused by the herpes simplex virus type I or herpes simplex type II (herpes lip skin of the face oral mucosa, skin of hands, ophthalmic herpes) subacute sclerosing panencephalitis, genital herpes with Varicella zoster virus (chicken pox and shingles, including relapse iviviruyu in patients with immunodeficiency), Epstein-Barr virus (infectious mononucleosis) cytomegalovirus, human papillomavirus, acute and chronic viral hepatitis B. Chronic recurrent infections of the respiratory tract and genitourinary system in patients with weakened immunity (including chlamydia and other diseases caused by the inside of the urogenital system in patients with immunocompromised pathogens).
Precautionary measures
It should be remembered that Normomed, like other antiviral agents for acute viral infections, is most effective if treatment is started at an early stage of the disease (preferably on the first day). The drug is used both for monotherapy and in complex treatment with antibiotics and other etiotropic agents. The active substance of the drug is metabolized to uric acid and can cause a significant increase in its concentration in the urine. In this regard, Normomed is used with caution in patients with gout and hyperuricemia in history of urolithiasis and renal insufficiency. If you need to use the drug in these patients, you must carefully monitor the concentration of uric acid. With prolonged use (3 months or longer), it is advisable to monitor monthly the concentration of uric acid in the blood serum and in the urine, liver function, the composition of the peripheral blood, and the parameters of the kidney function. Elderly patients. There is no need to change the dose of the drug is used in the dose for adults. Elderly patients more often than middle-aged people have an increase in serum and uric acid levels in the urine. Syrup contains 13 g of sucrose per dose, so it is used with caution in diabetic patients. The preparation includes methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216) which can cause allergic reactions (possibly delayed) and in some cases bronchospasm.
Use during pregnancy and lactation
The drug is not recommended to prescribe during pregnancy and lactation due to the lack of clinical studies of use during pregnancy and lactation.
Dosage and administration
The drug is taken orally better - after a meal at regular intervals. The duration of treatment is determined individually depending on the nosology of the severity of the process and the frequency of relapses; on average, the duration of treatment is 5-14 days, if necessary, after a 7-10-day break, the treatment is repeated. Treatment with interruptions and maintenance doses can last up to 1-6 months. The dosage is determined individually depending on the age of the body mass of the severity of the process. The maximum daily dose for adults is 4 g of inosine pranobex which corresponds to 80 ml of syrup.syrup 3-4 times a day, children - daily dose at the rate of 50 mg / kg (ie 1 ml syrup / kg) body weight in 3-4 doses for 5-7 days if necessary, continue treatment or repeat after 7 -8 days. In order to achieve the greatest effectiveness in case of acute respiratory viral infections, it is better to begin treatment at the first symptoms of the disease or from the first day of the disease. As a rule, the drug is taken 1-2 days after the disappearance of symptoms of bronchitis of viral etiology: adults - 20 ml syrup 3 times a day for children - daily dose at the rate of 50 mg / kg (ie 1 ml syrup / kg) in 3-4 receiving within 2-4 weeks of epidemic mumps: daily dose at the rate of 70 mg / kg (that is, 1 4 ml of syrup / kg) in 3-4 doses for 7-10 days; measles: daily dose at the rate of 100 mg / kg (that is, 2 ml of syrup / kg) in 3-4 doses for 7-14 daystomatitis: adults - 20 ml of syrup 4 times a day for children - daily dose based on 70 mg / kg (that is, 1 4 ml of syrup / kg) in 3 -4 reception ma for 6-8 days (acute phase), later adults - 20 ml of syrup 3 times a day for children - 50 mg / kg (i.e. 1 ml of syrup / kg) in 3-4 doses 2 times a week for 6 weeks, infectious mononucleosis: daily dose at the rate of 50 mg / kg (ie, 1 ml syrup / kg) in 3-4 doses for 8 days; cytomegalovirus infection: daily dose at the rate of 50 mg / kg (ie, 1 ml syrup / kg) in 3-4 doses for 25-30 days-shingling and labial herpes: adults - 20 ml of syrup 3-4 times a day children - daily dose based on 50 mg / kg (i.e. 1 ml of syrup / kg) in 3-4 doses for 10-14 days (until symptoms disappear), genital herpes: in the acute period - 20 ml of syrup 3 times a day for 5-6 days in the period of remission, maintenance dose - 20 ml syrup (1000 mg) 1 time per day for up to 6 months subacute sclerosing panencephalitis: daily dose at the rate of 50-100 mg / kg (i.e. 1-2 ml syrup / kg) for 6 doses (every 4:00) within 8-10 days after an 8-day break with a light course, an additional 1-3 courses with severe course - up to 9 courses, infections caused by Human papilloma virus (genital warts): 20 ml per Europe 3 times a day, the course of treatment - 14-28 days or in combination with cryotherapy or CO 2 -laser therapy - 20 ml of syrup 3 times a day 3 courses with an interval of 1 month of hepatitis B: adults - 20 ml of syrup 3-4 times daily for 15-30 days in the future maintenance dose - 20 ml of syrup (1000 mg) 1 time per day for 2-6 months chronic relapsing infections of the respiratory tract and urinary system in immunocompromised patients (in complex treatment): adults - 20 ml of syrup 3-4 times a day, the course of treatment - from 2 weeks to 3 months children - daily to and the rate of 50 mg / kg (i.e.1 ml of syrup / kg) in 3-4 doses for 21 days (or 3 courses of 7-10 days with the same breaks). To restore the function of the immune system and achieve a stable immunomodulatory effect in patients with weakened immunity, the treatment should last from 3 to 9 weeks.
Side effects
The drug is generally well tolerated even with prolonged use. A frequent adverse reaction is a short-term and insignificant (usually within the normal range) increase in the concentration of uric acid in the blood serum and in the urine (caused by inosine metabolism) which normalizes several days after the end of the drug intake. Other adverse reactions reported in the course of clinical studies on the use of inosine pranobex for 3 months or longer as well as in the post-marketing period and which are classified as frequent (> 1% of cases) rare (<1% of cases) and rare (<0 01%). Often (> 1%): Nervous system: headache dizziness increased fatigue ill state of the gastrointestinal tract: nausea with or without vomiting pain in the epigastric region, from the skin and subshircous tissue: itchy skin rashes, from the liver and biliary ducts: increased levels of transaminase alkaline phosphatase or blood urea nitrogen. From the side of the musculoskeletal and connective tissue: pain in the joints. Rare (<1%): from the nervous system: nervousness drowsiness or sleeplessness of the gastrointestinal tract: d Ares zaporso kidney side and urinary tract: polyuria (increased urine volume) .Redkie (<0. 01%) of the skin and subcutaneous tissue: krapivnitsaso the immune system: hypersensitivity reactions (including angioneurotic edema)
Overdose
Cases of overdose were not observed. Overdose can cause an increase in the concentration of uric acid in the serum and in the urine. In case of overdose, gastric lavage and symptomatic therapy are indicated.
Interaction with other drugs
Patients who take xanthine oxidase inhibitors (for example, allopurinol) and agents that increase uric acid excretion in the urine, including thiazide diuretics (for example, hydrochlorothiazide chlorothalidone indapamide) and loop diuretics (furosemide Torsemide ethacrine acid) are prescribed with caution.Normomed syrup is not used simultaneously with immunosuppressants because of possible pharmacokinetic interaction that may affect the expected therapeutic effect. Simultaneous use with zidovudine (azidothymidine) enhances the formation of nucleotides by zidovudine through various mechanisms, which leads to an increase in serum bioavailability of zidovudine and increased intracellular phosphorylation in monocytes. This leads to increased effects of zidovudine under the action of Normoded.